Literature DB >> 22244019

Role of moxifloxacin for the treatment of community-acquired [corrected] complicated intra-abdominal infections in Taiwan.

Yeu-Jun Lau1, Yen-Hsu Chen, Ching-Tai Huang, Wen-Sen Lee, Cheng-Yi Liu, Jien-Wei Liu, Hsiao-Dong Liu, Yuarn-Jang Lee, Chao-Wen Chen, Wen-Chien Ko, Po-Ren Hsueh.   

Abstract

Complicated intra-abdominal infections (cIAIs) are common yet serious infections that can potentially lead to substantial morbidity and morbidity. As an essential adjunct to source control, the goals of antimicrobial therapy are to promote patient recovery, reduce recurrence risk, and prevent antimicrobial resistance. The current international guidelines on the empirical treatment of community-acquired complicated IAIs were published by the Infectious Diseases Society of America (IDSA) and Surgical Infections Society (SIS) in 2010. These guidelines all recommend the use of a fluoroquinolone (ciprofloxacin or levofloxacin) plus metronidazole for mild-to-moderate- and high-severity cases. Moxifloxacin monotherapy is recommended by the current IDSA/SIS guidelines for the treatment of mild-to-moderate complicated IAIs. Moxifloxacin has demonstrated a broad spectrum coverage of both aerobic and anaerobic pathogens, good tissue penetration into the gastrointestinal tract, and a good tolerability profile. Clinical data have demonstrated that moxifloxacin is at least as effective as other standard therapeutic regimens recommended by current clinical guidelines. Due to the high rates of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and fluoroquinolone-resistant Enterobacteriaceae among isolates causing community-acquired IAIs in Asia, any fluoroquinolones (including moxifloxacin) are not recommended as drugs of choice for the empirical treatment of community-acquired IAIs, particularly in countries (China, India, Thailand, and Vietnam) with fluoroquinolone resistance rates among Escherichia coli isolates of >20%. Given the low rates of fluoroquinolone-resistant (<20%) and extended-spectrum β-lactamase (ESBL)-producing (<10%) Enterobacteriaceae isolates associated community-acquired IAIs in Taiwan, it appears that moxifloxacin is considered an appropriate first-line therapy for patients with community-acquired complicated IAIs in this country.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22244019     DOI: 10.1016/j.jmii.2011.11.010

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  4 in total

1.  Efficacy and safety of moxifloxacin in hospitalized patients with secondary peritonitis: pooled analysis of four randomized phase III trials.

Authors:  Jan J De Waele; Jose M Tellado; Günter Weiss; Jeffrey Alder; Frank Kruesmann; Pierre Arvis; Tajamul Hussain; Joseph S Solomkin
Journal:  Surg Infect (Larchmt)       Date:  2014-05-15       Impact factor: 2.150

2.  Bacterial culture and antibiotic susceptibility in patients with acute appendicitis.

Authors:  Dae Woon Song; Byung Kwan Park; Suk Won Suh; Seung Eun Lee; Jong Won Kim; Joong-Min Park; Hye Ryoun Kim; Mi-Kyung Lee; Yoo Shin Choi; Beom Gyu Kim; Yong Gum Park
Journal:  Int J Colorectal Dis       Date:  2018-02-27       Impact factor: 2.571

3.  Bacteriology and changes in antibiotic susceptibility in adults with community-acquired perforated appendicitis.

Authors:  Hong Gil Jeon; Hyeong Uk Ju; Gyu Yeol Kim; Joseph Jeong; Min-Ho Kim; Jae-Bum Jun
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

4.  The efficacy of combined therapy with metronidazole and broad-spectrum antibiotics on postoperative outcomes for pediatric patients with perforated appendicitis.

Authors:  Qingjuan Shang; Qiankun Geng; Xuebing Zhang; Chunbao Guo
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.